Tag: INCLUSIONS
TREATMENT OF ALZHEIMER’S DISEASE WITH NANOLITHIUM: FIRST INCLUSIONS OF PATIENTS IN THE PHASE II CLINICAL STUDY – 06/13/2022 at 08:00
Montpellier, June 13, 2022 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® technology for administering active ingredients in nano micelles…
MEDESIS PHARMA: TREATMENT OF ALZHEIMER’S DISEASE WITH NANOLITHIUM: FIRST INCLUSIONS OF PATIENTS IN THE PHASE II CLINICAL STUDY
MEDESIS PHARMA: TREATMENT OF ALZHEIMER’S DISEASE WITH NANOLITHIUM: FIRST INCLUSIONS OF PATIENTS IN THE PHASE II CLINICAL STUDY Subscribe Company Name MEDESIS PHARMA SA ISN FR0010844464 market Euronext Growth symbol…